The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
8,499
Sort by:
Apolipoprotein A (APOA or LPA) - Drugs in Development, 2021
US$ 3,000.00
Apolipoprotein A (APOA or LPA) - Drugs in Development, 2021 SUMMARY Apolipoprotein A (APOA or LPA) - Drugs in Development, 2021 provides in depth analysis on Apolipoprotein A (APOA or LPA) targeted pi...
April 2021
30 pages
Apolipoprotein A I (APOA1) - Drugs in Development, 2021
US$ 3,000.00
Apolipoprotein A I (APOA1) - Drugs in Development, 2021 SUMMARY Apolipoprotein A I (APOA1) - Drugs in Development, 2021 provides in depth analysis on Apolipoprotein A I (APOA1) targeted pipeline thera...
April 2021
35 pages
Apolipoprotein C III (APOC3) - Drugs in Development, 2021
US$ 3,000.00
Apolipoprotein C III (APOC3) - Drugs in Development, 2021 SUMMARY Apolipoprotein C III (APOC3) - Drugs in Development, 2021 provides in depth analysis on Apolipoprotein C III (APOC3) targeted pipeline...
April 2021
35 pages
Apolipoprotein E (APOE) - Drugs in Development, 2021
US$ 3,000.00
Apolipoprotein E (APOE) - Drugs in Development, 2021 SUMMARY Apolipoprotein E (APOE) - Drugs in Development, 2021 provides in depth analysis on Apolipoprotein E (APOE) targeted pipeline therapeutics....
April 2021
45 pages
Arthritis (Musculoskeletal) - Drugs in Development, 2021
US$ 2,000.00
Arthritis (Musculoskeletal) - Drugs in Development, 2021 SUMMARY Arthritis (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Arthritis pipeline landscape. The report provides...
April 2021
105 pages
Ascites (Gastrointestinal) - Drugs in Development, 2021
US$ 2,000.00
Ascites (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Ascites (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Ascites pipeline landscape. The report provides comp...
April 2021
30 pages
Astrocytoma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Astrocytoma (Oncology) - Drugs in Development, 2021 SUMMARY Astrocytoma (Oncology) - Drugs in Development, 2021 provides an overview of the Astrocytoma pipeline landscape. The report provides comprehe...
April 2021
55 pages
B-Cell Leukemia (Oncology) - Drugs in Development, 2021
US$ 2,000.00
B-Cell Leukemia (Oncology) - Drugs in Development, 2021 SUMMARY B-Cell Leukemia (Oncology) - Drugs in Development, 2021 provides an overview of the B-Cell Leukemia pipeline landscape. The report provi...
April 2021
100 pages
B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021
US$ 3,000.00
B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021 SUMMARY B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021 provides in depth analysis on B Cell Lymphoma 2 (Bcl 2) targeted pipeline therapeu...
April 2021
50 pages